Edgewise Therapeutics, Inc. - 10-Q Filing
Edgewise Therapeutics filed its 10-Q for the quarter ended March 31, 2026, providing unaudited financial statements and updates on its operations. The filing includes details on stockholders' equity, including retained earnings, additional paid-in capital, and accumulated other comprehensive income. It also outlines equity incentive plans, including the 2021 and 2024 plans, and financial assets such as money market funds and U.S. Treasury securities.
Tickers: $EWTX